Kanada - prancūzų - Health Canada

hoffmann-la roche limited - isotrétinoïne - capsule - 10mg - isotrétinoïne 10mg - misc. skin and mucous membrane agents

Kanada - prancūzų - Health Canada

hoffmann-la roche limited - isotrétinoïne - capsule - 40mg - isotrétinoïne 40mg - misc. skin and mucous membrane agents

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

roche registration gmbh - ocrelizumab - sclérose en plaque - immunosuppresseurs - traitement des patients adultes présentant des formes récidivantes de sclérose en plaques (rms) avec une maladie active définie par des caractéristiques cliniques ou d'imagerie. le traitement de patients adultes atteints de début de primaire progressive de la sclérose en plaques (pmp) en termes de durée de la maladie et le niveau de handicap, et avec des fonctions d'imagerie caractéristique de l'activité inflammatoire.

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

roche registration limited - emicizumab - hémophilie a - antihémorragiques - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra peut être utilisé dans tous les groupes d'âge.

Kamerūnas - prancūzų - DPML (Direction de la Pharmacie du Médicament et des Laboratoires)

roche - bromazepam - comprimé / tablet - 6 mg

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - lymphome À cellules b - agents antinéoplasiques - polivy en combinaison avec bendamustine et rituximab est indiqué pour le traitement des patients adultes en rechute/réfractaire diffus à grandes cellules b lymphome (lmnh) qui ne sont pas des candidats pour la greffe de cellules souches hématopoïétiques. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - agents antinéoplasiques - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

roche registration gmbh - baloxavir marboxil - grippe humaine - antiviraux à usage systémique - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - néoplasmes du sein - agents antinéoplasiques - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunosuppresseurs - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.